Sleep Disorders Trial, Recruiting (NCT05429983)

Sleep Disorders Trial, Recruiting NCT05429983 Sponsor: Johns Hopkins University Condition: Sleep Disorders

Printed from Voxsanity (voxsanity.com.au) — NCT05429983 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sleep Disorders

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People (male or female) who have moderate or severe sleep apnea, meaning they stop breathing or have very shallow breathing more than 15 times per hour during sleep.
People who are already scheduled to have a procedure called DISE (a sleep evaluation where a camera is used to look at the airway) as part of routine assessment for a specific type of implanted sleep apnea device (Inspire hypoglossal nerve stimulation), or because that device has not been working effectively for them.

Who may not be able to join:

People with serious heart disease, or who have had a recent or unstable heart event.
People with an active lung, liver, or kidney condition.
People with high blood pressure that is not well controlled (blood pressure above 160/100).
People with a disease that affects the muscles or nerves (neuromuscular disease).
People with a major mental health condition.
People who are pregnant.
People who are taking blood-thinning medications, such as Coumadin (warfarin) or Dabigatran.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 8 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kevin Motz, MD, Johns Hopkins University

Phone: 410614245

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05429983

Sponsor: Johns Hopkins University

Phase: Not Applicable

Status: Recruiting

Condition: Sleep Disorders

Trial contact: 410614245

More information: https://clinicaltrials.gov/study/NCT05429983

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People (male or female) who have moderate or severe sleep apnea, meaning they stop breathing or have very shallow breathing more than 15 times per hour during sleep.
People who are already scheduled to have a procedure called DISE (a sleep evaluation where a camera is used to look at the airway) as part of routine assessment for a specific type of implanted sleep apnea device (Inspire hypoglossal nerve stimulation), or because that device has not been working effectively for them.

Who may not be able to join:

People with serious heart disease, or who have had a recent or unstable heart event.
People with an active lung, liver, or kidney condition.
People with high blood pressure that is not well controlled (blood pressure above 160/100).
People with a disease that affects the muscles or nerves (neuromuscular disease).
People with a major mental health condition.
People who are pregnant.
People who are taking blood-thinning medications, such as Coumadin (warfarin) or Dabigatran.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 8 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Johns Hopkins University

Registry

ClinicalTrials.gov

Start date

29 November 2022

Est. completion

29 November 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Tidal airflow with direct genioglossus stimulation; HGNS therapy success as assessed by the apnea hypopnea index

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov